A toxic condition resulting from kidney disease in which there is retention in the bloodstream of waste products normally excreted in the urine. Also called azotemia.
M2 PHARMA-June 26, 2019-US FDA Accepts Supplemental Biologics License Application for Ultomiris (ravulizumab-cwvz) under Priority Review for the Treatment of Atypical Hemolytic Uremic Syndrome
Alexion Pharmaceuticals announced that the FDA has accepted for priority review the company's supplemental Biologics License Application for Ultomiris, the company's long-acting C5 complement inhibitor, for the treatment of people with atypical hemolytic uremic syndrome in order to inhibit complement-mediated thrombotic microangiopathy.
Recovery occurred more often in patients with vasculitis (11 percent at two years; adjusted hazard ratio, 20.4), ischemic kidney failure (12 percent; adjusted hazard ratio, 11.4), and hemolytic uremic syndrome (13 percent; adjusted hazard ratio, 15.6), compared to patients with congenital anomalies of the kidney and urinary tract.
For those patients, a complement-mediated TMA secondary to a dysregulation of the alternative complement pathway, classically called atypical haemolytic and uremic syndrome (a-HUS), should be suspected.
Calcific uremic arteriolopathy can be characterized by obstructive vasculopathy, with calcification of small arteries and arterioles resulting in luminal occlusion and subsequently cutaneous necrosis [1].
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.